Trials / Completed
CompletedNCT02084901
Comparison of Biodegradable Stents: Orsiro and BioMatrix
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The use of a biodegradable polymer has the potential to reduce the sustained inflammatory response of the arterial wall, facilitating re-endothelialization and minimizing the risk of thrombus formation and late restenosis. In the study, we are going to two biodegradable polymer stents, Orsiro and BioMatrix, especially regarding the stent strut coverage by optical coherence tomography at 3 months after stent implantation. The primary objective of this study is to test the hypothesis that Orsiro is non-inferior to Biomatrix in terms of stent strut coverage by optical coherence tomography at 3 months. The secondary endpoint is clinical outcomes up to 1 year.
Detailed description
The use of a biodegradable polymer has the potential to reduce the sustained inflammatory response of the arterial wall, facilitating re-endothelialization and minimizing the risk of thrombus formation and late restenosis. In the study, we are going to two biodegradable polymer stents, Orsiro and BioMatrix, especially regarding the stent strut coverage by optical coherence tomography at 3 months after stent implantation. The primary objective of this study is to test the hypothesis that Orsiro is non-inferior to Biomatrix in terms of stent strut coverage by optical coherence tomography at 3 months. The secondary endpoint is clinical outcomes up to 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Drug-eluting biodegradable stent Orsiro implantation | Drug-eluting biodegradable stent Orsiro implantation |
| DEVICE | Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation | Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-03-01
- Completion
- 2016-03-01
- First posted
- 2014-03-12
- Last updated
- 2016-07-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02084901. Inclusion in this directory is not an endorsement.